[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356101-105":59,"doc-detail-356101-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tumor-responsive-delivery-of-5-fluorouracil-from-a-redox-triggered-supramolecular-gelator-abstract-and-introduction","Tumor-Responsive Delivery of 5-Fluorouracil from a Redox-Triggered Supramolecular Gelator - Abstract and Introduction","","5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used against gastrointestinal cancers, but systemic toxicity and limited control of biodistribution restrict clinical utility. The study presents a redox-sensitive covalent conjugate, 5-FU-SS-lFF, linking 5-FU to the self-assembling heterochiral tripeptide DLeu-Phe-Phe. The conjugate forms supramolecular hydrogels with rheology comparable to lFF gels and releases 5-FU under reducing conditions found in tumor microenvironments. Enhanced release selectivity over 24 h yields pronounced cytotoxicity in hepatocellular carcinoma spheroids, supporting peptide-based smart hydrogels for targeted anticancer delivery.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-responsive-delivery-of-5-fluorouracil-from-a-redox-triggered-supramolecular-gelator-abstract-and-introduction/356101/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-responsive-delivery-of-5-fluorouracil-from-a-redox-triggered-supramolecular-gelator-abstract-and-introduction/356101.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is targeted delivery of 5-FU needed?","Question",{"text":113,"@type":114},"Systemic toxicity and limited clinical control reduce the utility of 5-FU, motivating targeted approaches that improve therapeutic efficacy while lowering harmful exposure.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the design of the 5-FU-SS-lFF conjugate?",{"text":118,"@type":114},"The work covalently links 5-FU to the self-assembling heterochiral tripeptide DLeu-Phe-Phe (lFF) using a redox-sensitive linker, enabling release under reducing conditions.",{"name":120,"@type":111,"acceptedAnswer":121},"How is drug release triggered and what evidence is provided?",{"text":122,"@type":114},"5-FU release is triggered under reducing conditions similar to those in the tumor microenvironment, with selective release demonstrated over 24 hours and associated cytotoxicity in hepatocellular carcinoma spheroids.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356101,1790668553,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","This article is licensed under CC-BY 4.0   \n[pubs.acs.org/bc](pubs.acs.org/bc)  Article   \nTumor-Responsive Delivery of 5‑Fluorouracil from a RedoxTriggered Supramolecular Gelator  \nMarko Mihajlovic, * Milos Mihajlovic, Paola Alletto, Slavko Kralj, Natalia Rosso, and Silvia Marchesan *  \n Cite This: Bioconjugate Chem. 2026, 37, 1571−1581  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: 5-Fluorouracil (5-FU) is a chemotherapeutic drug that is widely used to treat gastrointestinal cancers (e.g., hepatocellular carcinoma). Unfortunately, its systemic toxicity limits its clinical utility; therefore, new means for its targeted delivery at the pathological site are highly sought after to enhance therapeutic efficacy. In this work, we describe a 5-FU covalent conjugate with the self-assembling, heterochiral tripeptide DLeu-Phe-Phe (lFF) via a redox-sensitive linker (5-FU-SS-lFF). The conjugate yields supramolecular hydrogels with rheological properties similar to those of lFF hydrogels and enables 5-FU release under reducing conditions, such as those present in the tumor microenvironment. We demonstrate the selectivity of the drug  \nrelease under such conditions over a period of 24 h, with consequent significant cytotoxicity on cancer cells, as demonstrated on hepatocellular carcinoma spheroids. Overall, this study opens new opportunities for peptide-based supramolecular hydrogels as versatile and smart vehicles for the selective release of anticancer drugs under tumor-like reducing conditions.  \n1. INTRODUCTION  \nHydrogels are well-established and appealing biomaterials for biomedical uses, specifically when used as versatile drug delivery platforms.1,2 Hydrogels serve to encapsulate, dissolve, and protect therapeutics, allowing for favorable control over their release both in time and space.3−5 In this way, drug bioavailability and efficacy can be improved, while at the sametime reducing toxicity due to high or uncontrolled dosages. Besides, hydrogels are often regarded as ideal materials in terms of biocompatibility, being composed of significant amounts of water and having viscoelastic properties similar to those of human tissues.6  \nAmong the multitude of hydrogel classes that can be employed for drug delivery, those based on peptides have been gaining particular attention, especially due to their biocompatibility and biodegradability.7−12 Compared to traditional covalently cross-linked polymeric hydrogels, peptide-based gels rely on noncovalent interactions, such as hydrogen bonds, π−π stacking, hydrophobic and electrostatic interactions, leading to native-like, dynamic materials that can be formed and biodegraded in vivo. Specifically, supramolecular hydrogels based on ultrashort peptides are attractive vehicles for drug delivery, also because they can be produced easily and at low cost on a large scale.13 Short heterochiral peptides composed of D- and L-amino acids stack into β-sheets that fibrillate, eventually leading to the formation of 3-D networksand hydrogels. The combination of D-and L-building blocks in short sequences is quite useful, since it not only enables turnlike conformers that are prone to self-assembly but also provides some resistance against protease-mediated hydrol-  \nysis.14 One of the most popular examples of such short heterochiral peptides that is able to reliably form robust hydrogels under a variety of experimental conditions, including multicomponent systems, is given by DLeu-Phe-Phe (lFF) . 15−17 This low-molecular-weight gelator has been previously used to noncovalently load and release various drugs, leading to sustained delivery over prolonged periods for hydrophobic molecules, 18 but suffering from burst release of more hydrophilic ones, such as 5-fluorouracil (5-FU), 19 thus limiting its applicability in cancer treatment.  \nThe advantages offered by supramolecular, ","cbCaikZD9gL4iLrp","https://ap.wps.com/l/cbCaikZD9gL4iLrp","pdf",3088922,11,"English","# Abstract\n# Introduction\n## Hydrogels as drug delivery platforms\n## Peptide-based and supramolecular hydrogel advantages\n## Heterochiral tripeptide (DLeu-Phe-Phe) and limitations for 5-FU\n## Rationale for redox-sensitive covalent conjugation","[{\"question\":\"Why is targeted delivery of 5-FU needed?\",\"answer\":\"Systemic toxicity and limited clinical control reduce the utility of 5-FU, motivating targeted approaches that improve therapeutic efficacy while lowering harmful exposure.\"},{\"question\":\"What is the design of the 5-FU-SS-lFF conjugate?\",\"answer\":\"The work covalently links 5-FU to the self-assembling heterochiral tripeptide DLeu-Phe-Phe (lFF) using a redox-sensitive linker, enabling release under reducing conditions.\"},{\"question\":\"How is drug release triggered and what evidence is provided?\",\"answer\":\"5-FU release is triggered under reducing conditions similar to those in the tumor microenvironment, with selective release demonstrated over 24 hours and associated cytotoxicity in hepatocellular carcinoma spheroids.\"}]","Tumor-Responsive Delivery of 5-Fluorouracil from a Redox-Triggered Supramolecular Gelator - Abstract and Introduction | PDF",1790123402,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e443999ede5b068b4d3da19dc130811.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09fd58b4f2a699d59e38f13cbe6e86c0.webp",982,1295,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e307cbec633570364d9b6091c133bd6d.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5447b94fac2bd55d1af8ef7fbfba6934.webp",980,1292]